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Abstract
Purpose—To evaluate systematically in real clinical settings whether functional genetic
variations in drug metabolizing enzymes influence optimized doses, efficacy, and safety of
antipsychotic medications.
Methods—DNA was collected from 750 patients with chronic schizophrenia treated with five
antipsychotic drugs (olanzapine, quetiapine, risperidone, ziprasidone and perphenazine) as part of
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Doses for each of
the medicines were optimized to 1, 2, 3, or 4x units in identically-appearing capsules in a double
blind design. We analyzed 25 known functional genetic variants in the major and minor
metabolizing enzymes for each medication. These variants were tested for association with
optimized dose and other relevant clinical outcomes.
Results—None of the tested variants showed a nominally significant main effect in association
with any of the tested phenotypes in European-Americans, African-Americans or all patients.
Even after accounting for potential covariates no genetic variant was found to be associated with
dosing, efficacy, overall tolerability, or tardive dyskinesia.
Conclusion—There are no strong associations between common functional genetic variants in
drug metabolizing enzymes and dosing, safety or efficacy of leading antipsychotics, strongly
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suggesting merely modest effects on the use of these medicines in most patients in typical clinical
settings.
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Pharmacogenetics; CYP 450; Drug Metabolizing Enzymes; Antipsychotics; Personalized
Medicine
INTRODUCTION
Drug metabolizing enzymes (DMEs) have been a key focus of pharmacogenetics since its
inception in the 1950s1,2. A large body of evidence collected over the proceeding decades by
various independent groups shows a direct impact of functional variations in DMEs on the
pharmacokinetic properties of medications metabolized by these enzymes3,4. This has been
particularly true for psychiatric drugs5-7. The above observations have led many to argue
that the genotypes of patients at key DME genes should be incorporated into clinical
decision–making, particularly dosing8,9. As a result, there is an increasing number of
companies and products that offer clinicians convenient ways to determine patient genotypes
at key DMEs. One product in particular, the Roche AmpliChip10, has been approved by the
FDA and is being billed as of specific relevance in the use of a broad range of antipsychotics
and antidepressants. Surprisingly, there are few data that clearly support the relevance of
DME variation to the decisions that clinicians make in the treatment of either schizophrenia
or depression.
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)11 assessed the
overall effectiveness of five antipsychotics in parallel in a double blind, randomized fashion.
This study design affords an important opportunity to assess how genetic variation among
patients may influence clinical decisions. We therefore systematically evaluated the impact
of known functional genetic variation in the major and minor DMEs for each tested drug on
the doses clinicians decided to prescribe in the CATIE study. Complementary to these
analyses we tested associations between these variants and drug response features related to
efficacy, safety and adherence to medication. Overall we found that even validated
functional variation in relevant enzymes has but marginal impact on dosing and continued
use of medicines. These results suggest that DME-based genotyping tests may be of limited
utility in guiding clinicians regarding the optimal use of these medicines in most patients,
and that direct assessment of phenotype should be considered as an alternative strategy to
optimize drug dosing in this patient population.
MATERIALS AND METHODS
Subjects
The study subjects were a subset of patients who had participated in the CATIE study,
described at length elsewhere12. Briefly, in Phase 1, patients were randomized to treatment
with one of five antipsychotic medications –perphenazine, olanzapine, quetiapine,
risperidone or ziprasidone – and followed for up to 18 months or until treatment
discontinuation for any reason13. If perphenazine as the Phase 1 treatment was discontinued,
patients entered Phase 1B in which they were randomly assigned to receive olanzapine,
quetiapine, or risperidone. Discontinuation of Phases 1, 1A and 1B led to Phase 2, in which
randomization pathways were offered14: Phase 2E compared open-label clozapine treatment
to double-blind treatment with olanzapine, quetiapine, or risperidone. Because of the lack of
blinding, clozapine is not considered in this report; Phase 2T compared double-blind
treatment with olanzapine, quetiapine, risperidone, or ziprasidone. Throughout the complex
design of study phases, no subject was randomized to any medication more than once.
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Patients were not allowed to take other antipsychotics while participating in the trial.
However, in order to mimic real-life settings, concomitant medications for any other
indications were not restricted.
Patients were given identically appearing capsules of their assigned drug and instructed to
take between 1 and 4 pills per day based on the judgment of the treating physician. Each
capsule contained 8 mg perphenazine; 7.5 mg olanzapine; 1.5 mg risperidone; 200 mg
quetiapine; or 40 mg ziprasidone.
The study was approved by the institutional review board at each site. Written informed
consent was obtained from the patients or their legal guardians. 756 study participants
consented to provide blood samples for genetic analysis (52.8% of patients who had
received at least one dose of treatment in CATIE).
Candidate Gene selection and Hypotheses Tested
All five of the antipsychotics used in CATIE are extensively metabolized into less active or
inactive metabolites (Table 5) and some are substrates for transporters active at the blood-
brain-barrier such as PgP (ABCB1, MDR1)15,16. The relevant DMEs have been thoroughly
screened for functional variation in coding and regulatory genomic regions17 and we
therefore concentrated our attention on such known polymorphisms. We have considered
any known or suspected functional polymorphism with minor allele frequency greater than
2% in either Caucasians and/or African-Americans (Supplementary Materials and Methods
Table S3), with the exception of CYP2D6 gene duplications.
Genotyping
All genetic variants, with the exception of the CYP2D6 polymorphisms, were genotyped by
TaqMan fluorescence based allelic discrimination18. Pre-made assays offered as Assay-by-
Demand were used when available, otherwise primers were designed using the Applied
Biosystems (ABI) Assay-by-Design tool (Applied Biosystems, Foster City, CA).
Polymerase chain reactions (PCRs) were carried out using 0.5x standard ABI protocol for a
5μl reaction volume (Supplementary Materials and Methods Table S1).
CYP2D6 genotyping was performed as described previously19,20, and included *2, *3, *4,
*5, *6, *9, *10, *17, *29 and *41. Primer sequences (IDT, Coralville, IA) and additional
details pertaining to all genotyping reactions are presented in the Supplementary Materials
and Methods Table S1. CYP2D6 allele nomenclature throughout this report uses the recently
revised allele definitions as established by the CYP2D6 nomenclature committee (http://
www.cypalleles.ki.se/).
Genetic Models
Within each treatment group analyses were performed separately for each DME. The genetic
models tested and the scheme by which genotypes were collapsed into phenotypes are
described in the Supplementary Materials and Methods (Table S2). Generally, we coded
genotype for each gene by the number of functional, active, gene copies present: 2, 1 or 0.
Haplotypes were inferred with PHASE version 2.1 for genes in which 2 SNPs were
genotyped (i.e. CYP3A5, UGT1A4, FMO3, ABCB1, CYP2C8 and CYP2C9) to determine
the number of active gene copies carried. Analyses were carried out assuming an additive
model (power calculations suggest that in situations where roughly 50% of known causal
variants have an additive component21, tests assuming additivity are more powerful than
unrestricted genotype tests (unpublished data))
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Phenotype Definitions and Statistical Analyses
To maximize statistical power, the analyzed independent cohorts included subjects who had
received one of the five medications in any treatment phase, given the fact that patients
could not receive any specific drug more than once throughout the trial.
Dosing—optimized dose was defined as the average of all doses (in capsule number)
prescribed from the fourth phase-visit and onward for a specific drug. A visual inspection
(DBG and IG) of dose prescription data in a subset of patients indicated frequently
fluctuating doses during the first three visits (i.e. a dosage ‘adjustment’ period) followed by
relatively stable subsequent regimens. The first doses were therefore excluded from
optimized dose definitions, and any patient treated for less than four visits was excluded
from the dose analyses. We also considered adherence to medication based on pill-count,
self-administered questionnaires and the judgment of CATIE personnel performed each visit
and summarized by quartiles reflecting 0-100% adherence. Patients were included in
analyses in phases for which their phase-averaged scores were at least 63%, reflecting
overall “usual” (51-75% of the time) adherence to medication. Since patients may be non-
compliant to medication due to either ADRs or inadequate efficacy, we tested separately the
effect of DME functional variation on adherence to medication as defined above.
Univariate analysis was used to test main effects of each candidate gene as the independent
variable versus optimized dose by way of least-squares regression. A multivariate model
was constructed using mixed stepwise regression, incorporating the following covariates:
age, gender, race (White, Black or other), weight at baseline or phase initiation, maximum
weight change throughout the relevant phase, trail phase, phase duration (measured by
number of visits), PANSS at baseline or phase initiation, PANSS change throughout the
relevant phase, phase-averaged CGJMA score, concomitant medications categorized by their
inhibitory or inductive effects on the study drugs, summarized in the Supplementary
Materials and Methods Table S4), smoking status, occurrence of severe ADRs, TD status
during the phase, antipsychotic treatment prior to study initiation, years since first treated
with antipsychotics, alcohol and drug abuse. When more than one enzyme was known to
metabolize a study drug the genotype status of the relevant DMEs was incorporated into the
model as a potential covariate to account for gene-gene correlations. Criteria for model
construction required each covariate to satisfy entry and exit p-values of 0.1 or less. Once
the covariate model was developed we compared it to the same model incorporating the
relevant genetic effect using the least squares test, as implemented in JMP IN22. The final
model was then tested for gene-by-race interaction and if a significant effect was detected
analyses were performed in each ethnic group independently.
Safety and efficacy assessment—We tested associations between relevant DME gene
variants and treatment discontinuation due to safety or inefficacy reasons. These analyses
included all patients treated in phases 1, 1A, 1B, 2E or 2T, with the exception of patients
discontinuing treatment due to “patient decision” or “subject advocate discontinuation”.
Additionally, patients discontinuing treatment due to lack of efficacy before the 4th phase-
visit were excluded from the efficacy tests. Analysis was performed in a similar manner to
that described for the dosing end-point.
Because of the expectation that poor metabolizers or individuals with reduced DME activity
may be at a higher risk to experience dose dependent ADRs and that extensive metabolizers
are more likely to show lower efficacy, we constituted two different tests:
a) discontinuation due to ADRs versus full phase completion
b) discontinuation due to inadequate efficacy versus full phase completion
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Tardive Dyskinesia—TD has been suggested to be a dose dependent ADR associated
with antipsychotic treatment, particularly “conventional”, typical drugs such as
perphenazine. TD status was determined based on the Schooler-Kane criteria for probable
TD23, for which patients were tested at baseline, every 3 months thereafter, and at phase
end24. Analyses were performed with the case group comprised of patients who were
positive for the probable TD criteria at least twice throughout their participation in the trial,
and the control group including all individuals who never met these criteria. Patients who
met the TD criteria only once during the trial were excluded from analyses (N=74). It should
be mentioned that while drug treatment immediately prior to CATIE participation was
included in the multivariate analysis (as described in the dosing section above), we had no
access to complete records of medical history.
Analyses were performed by R version 2.3.025 and by JMP IN version 5.122 separately and
independently within each drug cohort. Hidden population stratification within each
ethnicity was not explored in detail. Simple Genomic Control methods were not pursued due
to the lack of any significant results. More sophisticated correction methods (e.g.
EIGENSTRAT26) which could correct for false negatives, require an extremely large
number of additional genotypes (>5,000) to be effective.
RESULTS
Genotyping results
All genotype calls were determined independently by at least two researchers and
ambiguous calls were re-genotyped or discarded. Genotyping failure rates were below 3%.
CYP2C19*3 showed a very low minor allele frequency (as expected) and was excluded
from all analyses. Upon testing for Hardy-Weinberg Equilibrium (HWE), one variant out of
a total of 16 TaqMan based assays had a p-value <0.05 (CYP2C19*2, p=0.035), due to a
deficiency of heterozygotes. It was re-genotyped, and the same genotypes for all samples
were obtained. Allele frequencies were compared to published data and confirmed to match
expected values (Supplementary Materials and Methods Table S1). Among the 10
genotyped CYP2D6 variants, HWE analysis was significant for the *5 deletion allele
(Fisher’s exact test p=0.0016) in Caucasians (out of 20 tests in total), the deviation again
being due to a deficiency of heterozygotes. The observed rate of significant p-values was
consistent with that expected under the null hypothesis. These samples, along with 24
randomly picked samples, were re-genotyped independently in a separate blinded laboratory
(AG) and were identically called.
Association Results
Optimized dose—We tested association between optimized dose (Figure 1) and genotype
within each relevant treatment group (Table 1).
None of the tested variants showed a significant main effect (p<0.05) in association with
optimized dose in European-American, African-Americans or all patients (Table 2). Even
after accounting for potential covariates no genetic factors were found to be associated with
dosing (Table 2).
Safety and efficacy—Treatment response phenotypes reflecting safety and efficacy were
tested by contrasting discontinuation counts due to unacceptable side effects (ADRs) and
inadequate efficacy versus successful phase completion (Table 3), respectively. No
nominally significant associations (p<0.05) were detected between the tested variants and
occurrence of ADRs in univariate analysis. When exploring potential confounding effects
via logistic regression analysis, few nominally significant associations were detected. The
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only association recorded (p=0.013) in the safety test suggested a correlation between the
lower activity variants in the FMO3 gene and higher incidence of ADRs in African-
Americans treated with olanzapine (N=59). No association was detected with this variant in
either the whole cohort or European-Americans alone. In the efficacy test we recorded two
marginally significant associations between the severely decreased activity genetic variants
in CYP3A5 and higher efficacy of quetiapine (p=0.02) and risperidone (p=0.04). None of
these results survives correction for multiple testing.
Tardive dyskinesia—Neither univariate nor regression analyses (Table 4) found the
exhibition of TD to be significantly associated (p<0.05) with the lower activity genetic
variants of the CYP2D6 and/or CYP1A2 genes.
Medication Adherence Assessment
We considered the effect of 23 different drug-DME combinations (Table 5) on two summary
indices of medication adherence (the mean of the treating clinician’s global judgment
scores; and the median proportion of pills taken) using non-parametric and parametric
analyses. These two indices showed an inverse correlation (Spearman ρ=−0.55). None of the
tests performed remained significant after adjustment for multiple testing (92 non-
independent tests). The most significant finding observed was for ABCB1 in subjects who
had received risperidone: non-parametric p=0.004 for clinician judgment based adherence
(False Discovery Rate27 (FDR)-adjusted p=0.19) and non-parametric p=0.04 for pill count
(FDR-adjusted p=0.36). Even if significance had been achieved, the magnitude of the effect
was very small: a median of 96% of pills taken for the ABCB1 haplotype “0” (coding
scheme available in the Supplementary Materials and Methods Table S2) versus 91% for all
other ABCB1 haplotype variants.
DISCUSSION
Despite the growing enthusiasm for using genetic diagnostics to guide clinical decision
making there remains scant evidence supporting the clinical utility of currently known
genetic differences among patients. For DME variants in particular there has been a strong
push toward their incorporation into the clinical use of antipsychotics, antidepressants and
other medicines. Here we have evaluated how known functional variation in all the major
DMEs for five antipsychotic drugs influences their clinical use in the context of a
randomized clinical trial. Despite the relative homogeneity of clinical decision making in
this setting (in comparison, for example, to care outside of a trial setting) and a
comprehensive set of clinical and genetic covariates tested we find no strong associations
between the relevant genetic variants and the safety or efficacy of the medicines or even
with their optimized doses. These results do not, of course, rule out modest effects or
potential impact of gene-gene and gene-environment synergies not well understood yet, that
may overall be clinically meaningful. Power analyses28 suggest, however, that our study
was well-powered to detect minimum genetic effects of between 6-20% of variance in the
dosing phenotype, as well as minimum genotype relative risks of between 1.6-2.7 for the
discontinuation tests. This suggests that in normal clinical settings DMEs variation has, at
best, modest effects on the use of these medicines.
A few inherent limitations in the current study should be noted. First, pharmacogenetic
variability in drug biotransformation is most likely to have clinical consequence when the
clearance of the drug is primarily or solely dependent on a single pathway. While CYP2D6
is the lead determinant of perphenazine clearance, alternative pathways may play important
roles (Table 5). As patients differ in their individual complement of hepatic and intestinal
CYPs, the clinical impact of CYP2D6 genotype and phenotype will vary depending on the
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relative importance of CYP2D6- vs non-CYP2D6-mediated clearance pathways. For
example, when expressed relative to the administered dose, median steady state
concentrations of perphenazine were almost double in CYP2D6 PMs compared to EMs, but
overlapped in range29. Secondly, risperidone and its CYP2D6-dependent metabolite, 9-
hydroxyrisperidone, are considered to have similar pharmacologic activity30 and are jointly
referred to as the active moiety. While a relationship between CYP2D6 genotype and
phenotypes, such as steady state serum risperidone concentration/dose ratios and
risperidone/9-hydroxyrisperidone ratios, has been established by several groups and has
potentially been associated with ADRs31, there appears to be no such relationship between
genotype and total active moiety32. On the other hand, any pathway affecting the latter (e.g.,
N-dealkylation by CYP3A33, Table 5) potentially confers prognostic value. Thirdly, the use
of genotype data to predict drug clearance and dose requirements or toxicity is particularly
difficult when enzyme activity demonstrates considerable variability in a particular
population and is inducible. For example, phenotypic differences in CYP1A2 activity are
more apparent in smokers34 (compelling us to perform analyses conditioned on smoking
status and consider smoking as a covariate in multiple regression models). However, it is
unclear what is the quantitative importance of the polymorphic pathway in the overall
disposition of a drug of interest35. Fourthly, interpretation and application of genotype
information is also compounded by knowledge of the likely functional consequences of the
genotyped SNP (or variants in linkage equilibrium) on the specific drugs of interest in
specific populations. One example is the CYP2D6*17 allele, which demonstrates “reduced”
activity towards dextromethorphan, bufuralol and debrisoquine, relative to the reference
CYP2D6*1 alleles, but has been reported to convey increased activity towards other
medications, such as haloperidol36 and risperidone37 in specific populations. Lastly, recently
published data indicates the potential of variants not explored in the current report to affect
drug response phenotypes, such as the recently reported CYP2C19*1738. The above
phenomena, if extends to other CYPs and substrates, may further obfuscate genotype-
phenotype relationships.
Reviewing the above articulated considerations, evidence for clinical utility of routine
genotyping of genes involved in drug biotransformation and transport likely will first be
limited to situations where a single, polymorphically expressed pathway is the primary route
of elimination in most treated patients, the drug is metabolized to inactive metabolites and
has a narrow range. More direct measurement of drug biotransformation phenotype, as
supplements to our estimations from genotype data, is currently being evaluated in a subset
of the CATIE subjects.
In summary, our results suggest that genotype information alone is a poor predictor of
antipsychotic drug disposition and response in a clinical situation. Caution is warranted
when using diagnostic products such as the Roche AmpliChip in absence of a clear
association between the tested variants and relevant clinical responses. More generally,
taken together with the report of no significant association between functional DME variants
and citalopram response in the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) trial39, these results may suggest that the importance of genetically controlled
variability in drug pharmacokinetics may often be modest. While improvements in
prediction of phenotypes by usage of genotype information are constantly being refined40,41,
prospective data demonstrating the utility of a priori DME genotype assessment for
optimizing treatment response are extremely limited. In this context, it should be mentioned
that variation in genes related to a medication’s mode of action may often have larger effects
than variants in genes influencing metabolism42,43, though it is too early to be certain how
general this will prove. What does appear likely is that if variation in genes governing the
pharmacodynamic properties of drugs does not prove to be more important than those
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governing pharmacokinetics, germline pharmacogenetics will have at best a very modest
clinical utility in many therapeutic areas, and specifically in psychiatry.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Histogram displaying the distribution of optimized doses (presented in number of pills
taken) in each of the five tested treatment groups
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Table 1
Description and Outcome Measures of Patients in the Optimized Dose Cohorts
Characteristic Olanzapine Quetiapine Risperidone Ziprasidone Perphenazine
Patients – OD cohort 195 151 175 96 91
Phase 1/1A 139 104 118 57 91
Phase 1B 17 22 12 0 0
Phase 2 39 25 45 39 0
Age – Mean yr ±SD
Sex – no. (%)
40.67±11.28 41.41±11.45 40.69±11.27 40.9±10.07 40.5±10.61
Male 141 (72.3) 117 (77.5) 131 (74.9) 74 (77.1) 64 (70.3)
Female 54 (27.7) 34 (22.5) 44 (25.1) 22 (22.9) 27 (29.7)
Race – no. (%)
Caucasian 124 (63.6) 106 (70.2) 117 (66.8) 61 (63.5) 58 (63.7)
African-American 63 (32.3) 39 (25.8) 53 (30.3) 29 (30.2) 27 (29.7)
Other 8 (4.1) 6 (4) 5 (2.9) 6 (6.3) 6 (6.6)
BL antipsychotic
medications $ – no. (%)
Olanzapine 71 (36.4) 43 (28.5) 50 (28.6) 23 (23.9) 28 (30.8)
Quetiapine 19 (9.7) 11 (7.3) 14 (8) 10 (10.4) 3 (3.3)
Risperidone 38 (19.5) 39 (25.8) 42 (24) 26 (27.1) 26 (28.6)
Perphenazine 0 7 (4.6) 5 (2.9) 1 (1) 1 (1.1)
Ziprasidone 11 (5.6) 8 (5.3) 9 (5.1) 3 (3.1) 2 (2.2)
None 47 (24.1) 35 (23.2) 38 (21.8) 28 (29.2) 25 (27.5)
Treatment disc. - no.
(%)
Ineffectiveness 25 (12.8) 49 (32.5) 45 (25.7) 23 (24) 19 (20.9)
ADRs 28 (14.4) 17 (11.3) 15 (8.6) 9 (9.4) 12 (14.3)
Administrative decision 8 (4.1) 5 (3.3) 4 (2.3) 4 (4.2) 1 (1.1)
Patient decision 10 (5.1) 19# (12.5) 15 (8.6) 15 (15.6) 7 (7.7)
Treatment completion 124 (63.6) 61 (40.4) 96 (54.9) 45 (46.9) 51 (56)
TD status – no. (%)
Probable 42 (21.5) 34 (22.5) 30 (17.1) 21 (21.9) 20 (22)
Definite 8 (4.1) 10 (6.6) 6 (3.4) 3 (3.1) 6 (6.6)
Weight (Lb)
Mean BL 197.7±48.33 200.29±45.54 199.65±52.67 201±45.93 191.57±47.73
Mean change/month 1.05±1.95 0.28±3.39 0.26±2.4 −0.53±3.13 −0.05±2.05
Max phase change 16.3±13.79 15.95±11.88 16.6±14.2 16.1±13.04 17.12±12.76
Concomitant
medications – no. (%)
Inhibitors** 34 (17.4) 31 (20.5) 28 (16) 21 (21.9) 14 (15.4)
Inducers** 12 (6.2) 5 (3.3) 5 (2.9) 3 (3.1) −
PANSS score
BL 75.10±19.1 74.1±16.7 75.7±16.8 71.1±14.8 71±17.6
Change −10.6±17.04 −3.9±18.6 −9.4±18.8 −2.7±18.9 −8.7±19.3













Grossman et al. Page 13
Characteristic Olanzapine Quetiapine Risperidone Ziprasidone Perphenazine
Smoking – no. (%) 131 (67.2) 105 (69.5) 124 (70.9) 74 (77.1) 66 (72.5)
Cigarettes/day – Mean
± SD
12.11±12.6 10.54±11.24 12.5±12 11.92±11.09 12.9±12.9
Alcohol abuse – no.**** (%) 16 (8.2) 19 (12.6) 19 (10.9) 6 (6.3) 6 (6.6)
Drug abuse – no. (%) 20 (10.3) 20 (13.2) 22 (12.6) 13 (13.5) 12 (13.2)
No. visits/phase –
Mean ± SD
Phase I/IA 14.48±5.15 11.8±5.44 13.68±5.25 12.21±5.52 13.1±5.6
Phase IB 9.88±3.95 10.77±3.9 10±3.54 − −
Phase II 13.35±5.17 7.12±3.89 12.27±5.25 8.23±3.62 −
Optimized dose -
Mean ± SD









14.69±11.76 13.23±10.28 13.18±11.47 13.75±10.67 13.37±10.57
Anticholinergic
treatment – no. (%)
BL 42 (21.5) 31 (20.5) 36 (20.6) 19 (19.8) 17 (18.7)
During phase 52 (26.7) 29 (19.2) 38 (21.7) 21 (21.9) 25 (27.5)
Abbreviations: OD, optimized dose; SD, standard deviation; BL, baseline; disc, discontinuation; ADRs, adverse drug reactions; TD, tardive
dyskinesia.
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Table 2
Association Analysis of all Relevant DME Genetic Effects on Optimized Dose in Univariate and Covariance
Analyses
Drug group Gene & variant Main effect Analysis ofcovariance
Effect size † p-value p-value
Perphenazine CYP2D6_combined β = +0.33 0.30 0.22
CYP1A2*1F β= +0.17 0.30 *
CYP2C8_combined β= −0.33 0.13 *
CYP2C9_combined β= −0.08 0.71 *
CYP2C19*2 β= −0.001 0.99 *
Risperidone CYP2D6_combined β = −0.07 0.64 0.17
CYP3A5_combined β= −0.12 0.24 0.49
CYP3A4*1B β= −0.06 0.53 *
ABCB1_combined β= −0.12 0.20 0.81
Olanzapine CYP1A2*1F β= −0.15 0.11 0.08
FMO3_combined β= −0.05 0.56 0.54
UGT1A4_combined β= +0.07 0.58 *
CYP3A5_combined β= −0.002 0.98 *
CYP1A4*1B β= +0.08 0.35 *
CYP2D6_combined β = −0.06 0.64 *
Quetiapine CYP3A5_combined β= +0.03 0.79 0.46
CYP3A4*1B β= +0.05 0.60 *
ABCB1_combined β= −0.001 0.99 *
CYP2D6_combined β = −0.04 0.78 *
CYP2C9_combined β= −0.01 0.94 *
Ziprasidone CYP3A5_combined β= −0.15 0.21 0.34‡
CYP3A4*1B β= −0.1 0.40 *
ABCB1_combined β= +0.02 0.88 *
β is the slope of the linear regression model defined by Y = α + β × X, where Y is optimized dose and X is the genetic factor tested. Annotation of
“gene_combined” relates to the sum functionality of the gene as reflected by the two haplotypes individuals carry (defined in Supplementary
Materials and Methods, Table 3).
*
Asterisks denote variants which were considered as potential covariates in the step-wise regression model.
Nominal p-values are reported.
†
Main effects are registered in reference to the lower/absent enzymatic activity genotypes, expecting the effect to be positive (i.e. lower activity
genotypes are expected to settle on lower optimized doses).
‡
Race-by-gene interaction term was statistically significant (p=0.04) in the ziprasidone cohort, but a multivariate analysis in each race group
separately yielded p= 0.36 and 0.12 for African-Americans and Caucasians, respectively.
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Table 5






























5 Perphenazine CYP2D6 CYP1A2 CYP2C9 CYP2C19 CYP2C8
Abbreviations: DME, drug metabolizing enzyme; CYP, cytochrome P450; AOX1, aldehyde oxidase 1; FMO3, flavin-containing monoxigenase 3;
ABCB1, p-glycoprotein (MDR1); UGT1A4, uridine 5′-diphosphate glucuronosyl transferase 1A4.
*
There are no common functional variants in AOX1 and inhibitors and inducers of the enzyme do not affect ziprasidone
pharmacokinetics44,4536, 37. AOX1 was thus not analyzed in this report.
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